Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Free Cash Flow (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Free Cash Flow data on record, last reported at -$14.1 million in Q3 2025.

  • For Q3 2025, Free Cash Flow fell 67.62% year-over-year to -$14.1 million; the TTM value through Sep 2025 reached -$50.9 million, up 7.78%, while the annual FY2024 figure was -$58.0 million, 1.68% down from the prior year.
  • Free Cash Flow reached -$14.1 million in Q3 2025 per NWBO's latest filing, down from -$7.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$7.0 million in Q2 2025 and bottomed at -$20.3 million in Q4 2024.
  • Average Free Cash Flow over 5 years is -$12.9 million, with a median of -$12.8 million recorded in 2021.
  • Peak YoY movement for Free Cash Flow: plummeted 83.75% in 2022, then surged 58.18% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$12.8 million in 2021, then grew by 13.99% to -$11.0 million in 2022, then tumbled by 57.83% to -$17.4 million in 2023, then decreased by 16.59% to -$20.3 million in 2024, then skyrocketed by 30.43% to -$14.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$14.1 million in Q3 2025, -$7.0 million in Q2 2025, and -$9.5 million in Q1 2025.